Dr. Aaron Gerds breaks down the outcomes of the phase 3 VERIFY trial, investigating rusfertide, for patients with polycythemia vera, a type of blood cancer.

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Big news! ASCO lands a major nine-figure contract with a North Sea operator. This game-changer highlights our 60 years of ...

Compared with chemotherapy alone, neoadjuvant nivolumab plus chemotherapy extends overall survival in patients with resectable non-small cell lung cancer.

Artificial intelligence (AI)-assisted training improves pathologist accuracy in human epidermal growth factor receptor 2 (HER2) immunohistochemistry (IHC) scoring in patients with breast cancer.

The oncology community has sounded the alarm over the Trump administration's 2026 budget proposal, which includes near-40% ...

Brian P. Mulherin, MD, shares his key takeaways from the 2025 ASCO Annual Meeting, highlighting significant advancements in SCLC and the challenge of information overload at large conferences.

Cancer researchers discovered how exercise really can be like a drug for colon cancer, and AstraZeneca's immunotherapy drug ...

Merus initially surged on superior interim trial data, while Bicara Therapeutics tanked. Click here to find out why BCAX ...

CHICAGO — Daily adjuvant aspirin did not reduce disease recurrence for patients with colorectal cancer liver metastases and ...

Lurbinectedin and atezolizumab performed better than atezolizumab alone as maintenance therapy for extensive-stage small cell lung cancer.

An analysis of oral presenters at ASCO Annual Meeting revealed considerable disparities based on career stage, gender, subspecialty and geographic region.Mid- to late-career medical oncologists from ...